Christie, E
Disclosures: Stephen Congly: Axcella Health, Inc.: Grant/Research Support, AstraZenica: Grant/Research Support, Merck: Grant/Research Support, Ipsen: Grant/Research Support, Bausch Health: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, AstraZeneca: Consultant, GSK: Consultant, Mayur Brahmania: Nothing to Disclose, Conar O'Neil: Gilead Sciences: Speaking and Teaching, Gilead Sciences: Advisor, AbbVie: Speaking and Teaching, ViiV: Advisor, ViiV: Speaking and Teaching, Karen Doucette: Roche: Grant/Research Support, GSK: Grant/Research Support, Altimmune: Grant/Research Support, Mang Ma: Nothing to Disclose, Carla Coffin: Gilead Sciences: Grant/Research Support, Janssen Pharmaceuticals: Grant/Research Support, GSK: Speaking and Teaching, Altimmune Pharmacueticals: Fund paid to the University of Calgary, Riche Pharmaceuticals: Grant/Research Support, GSK: Funds paid to the University of Calgary 1709 VARIATION IN NULEOS(T)IDE ANALOGUE USE IN MEDICARE PART D THROUGHOUT THE UNITED STATES Stephen Congly 1 Conar O'Neil 2 Karen Doucette 2 Mang Ma 2 Mayur Brahmania 1 Carla Coffin 1 , 1 University of Calgary, 2 University of Alberta Background: Treatment for chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) suppresses viral replication and prevents progression to fibrosis and liver cancer
10.1016/j.nutres.2013.08.009 297
Under glucose deprivation, tumor cells rely on an alternative energy-generating pathway such as glutaminolysis [25,67] [Figure 1D]
